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Certain serine proteases are considered to be signal-
ing molecules that act through protease-activated re-
ceptors (PARs). Our recent studies have implicated
PAR1 and PAR4 (thrombin receptors) and PAR2 (tryp-
sin receptor) in human colon cancer growth. Here we
analyzed the expression of KLK4, a member of the
kallikrein-related peptidase (KLK) family of serine
proteases and explored whether this member can
activate PAR1 and PAR2 in human colon cancer cells.
Immunohistochemistry showed KLK4 expression in
human colon adenocarcinomas and its absence in
normal epithelia. KLK4 (1 mol/L) initiated loss of
PAR1 and PAR2 from the HT29 cell surface as well as
increased intracellular calcium transients in HT29
cells. This KLK4-induced Ca2 flux was abrogated af-
ter an initial challenge of the cells with TRAP (SFLLR-
NH2; 100 mol/L), which is known to desensitize
PAR1 and PAR2. Interestingly, PAR1 blocking anti-
body, which inhibits cleavage and activation by
thrombin, dramatically reduced KLK4-induced Ca2
influx, but blocking cleavage of PAR2 failed to atten-
uate the KLK4-induced Ca2 flux. Consistently, de-
sensitization with AP1 (TFFLR-NH2), targeting PAR1,
attenuated most of the Ca2 flux induced by KLK4.
KLK4 also induced a rapid and significant ERK1/2
phosphorylation in HT29 cells. Our results demon-
strate, for the first time, that KLK4 is aberrantly ex-
pressed in colon cancer and capable of inducing PAR1
signaling in cancer cells. These data suggest that KLK4
signaling via PAR1 may represent a novel pathway in
colon tumorigenesis. (Am J Pathol 2010, 176:1452–1461;
DOI: 10.2353/ajpath.2010.090523)
The progression from normal colonic mucosa to malig-
nant tumor is a multistep process involving genetic alter-
ations in oncogenes and/or tumor suppressor genes that
lead to aberrant growth.1,2 Proteases have long been
associated with colon cancer progression because of
their ability to degrade extracellular matrices, which fa-
cilitates invasion and metastasis.3 However, recent stud-
ies have shown that these enzymes target a diversity of
substrates and promote some steps of tumor develop-
ment.4 The traditional view of the role of proteases in
tumor growth and progression has therefore significantly
changed recently. Besides their contribution to cancer
progression by degrading extracellular matrix proteins, it
is now clear that a subclass of proteases serve as
signaling molecules controlling cell functions through
specific membrane receptors, the protease-activated
receptors (PARs).5,6 PARs are seven transmembrane-
spanning G protein–coupled receptors that are targeted
by a variety of serine proteases and also by enzymes
from other protease families including matrix metallopro-
tease-1.6–8 To date four members of the family have
been described: PAR1 to PAR4.6,9 Originally, PAR1,
PAR3, and PAR4 were described to be activated only by
thrombin, whereas PAR2 is activated by trypsin and mast
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cell tryptase but not by thrombin. Cleavage of PARs by
activating serine proteases exposes a new amino terminus
that functions as a tethered ligand. This new ligand binds to
the core of the receptor and initiates signal transduction
resulting in stimulation of phosphoinositide breakdown and
cytosolic calcium mobilization.5,6 Short synthetic peptides
(activating peptides or APs) corresponding to the newly
exposed amino terminus are able to selectively activate a
given PAR receptor and mimic cellular effects of the
protease.5,6,10
We have previously demonstrated that trypsin acts
through PAR2 as a very robust growth factor for human
colon cancer cells.11 Moreover, we have shown that the
thrombin receptors PAR1 and PAR4 are aberrantly ex-
pressed in human colon cancer cells in vivo and in vitro
and their activation induces cell proliferation and mo-
tility in human colon cancer cells.12,13 The mechanism
by which PARs control proliferation involves a series of
events that lead to the activation of ERK1/2.14,15 These
data support the idea that PARs as well as their activators
may be considered as important contributors to the de-
velopment of human colon cancer. Since their initial char-
acterization, many PAR-activating serine proteases have
been reported, including cathepsin G, epithelial trypsin
IV, and mesotrypsin.6,9,16–18 The discovery of novel PAR
activators has generated additional interest in the possi-
ble role of PAR receptors in cancer biology. However, the
physiological activators of PARs in colonic tumors have
not been characterized yet. Very recently, some mem-
bers of the tumor-associated serine protease family of
kallikrein-related peptidases (KLK) have been shown to
function as PAR activators in vitro and in vivo.19 These
findings have been partially confirmed in vitro by others
who demonstrated the ability of KLK5 and KLK14 to
activate PAR2 by analyzing calcium mobilization in cells
stably transfected with PAR2,20 whereas in prostate can-
cer cells, KLK4 and KLK2 were found to initiate cell
signaling.21,22
The KLK superfamily consists of fifteen (KLK1–KLK15)
trypsin- or chymotrypsin-like serine proteinases.23 KLK
proteases, which are secreted into the extracellular
space of a wide range of tissues, are involved in a num-
ber of physiological processes24 and malignancies in-
cluding tumor establishment, growth, and/or metasta-
sis.25 Recently, we have structurally and biochemically
characterized a series of KLK proteases including
KLK4.26 KLK4 is a trypsin-like serine protease displaying
arginine/lysine-specific protease activity27 similar to the
known PAR activators.6 In this context, the purpose of this
study was to determine KLK4 expression in colon cancer
tumors in vivo and to examine its ability to modulate PAR
activity and signaling in HT29 colon cancer cells in vitro.
Our results demonstrate for the first time the aberrant
expression of KLK4 in colonic tumors and show its ability
to induce PAR1 signaling that promoted ERK1/2-MAP
kinase activation in colon cancer cells. These results
provide a link between the increased expression of KLK4
and the ectopic expression of PAR1 in colon cancer.
Thus, we can speculate that KLK4 is a potential endog-
enous activator of PAR1.
Materials and Methods
Reagents
The reagents were obtained from the following sources: the
activating peptides TFLLR-NH2 (AP1), and SLIGKV-NH2
(AP2) or SFLLRN-NH2 (TRAP, thrombin receptor agonist
peptide that activates both PAR1 and PAR2), NeoMPS
(Strasbourg, France); 2- furoyl-LIGRLO-NH2 (gift from Dr
Hollenberg, Calgary, Canada); highly purified -thrombin
(3000 U/mg), Kordia Laboratory Supplies (Leiden, Nether-
lands); trypsin (16,000 U/mg), goat anti-mouse IgG coupled
to fluorescein, Sigma Chemical Co. (St Louis, MO); Fura-2-
AM, Molecular Probes (Leiden, Netherlands). Antibodies
were purchased from the following vendors: phospho-
specific antibodies to ERK1/2, Cell Signaling Technologies
(Beverly, MA); polyclonal anti-ERK1/2 antibodies, Santa
Cruz Biotechnology (Santa Cruz, CA); WEDE-15 and
SPAN-12 monoclonal antibodies,28 Beckman Coulter (Vill-
epinte, France). All other chemicals were purchased from
Interchim (Asnie`re, France).
Cell Culture
The human colon cancer cell line HT29 was obtained from
the American Type Culture Collection (Rockville, MD). Cells
underwent routine culture in 25-cm2 plastic flasks (Costar,
Cambridge, MA) and were maintained at 37°C in a humid-
ified atmosphere of 5% CO2/air in Dulbecco’s modified
Eagle’s medium, Invitrogen (Cergy Pontoise, France) con-
taining 4.5 g glucose/L, supplemented with 10% fetal calf
serum.
Recombinant Kallikrein-Related Peptidase 4
Recombinant KLK4 was expressed in E. coli and purified as
described previously.27 Briefly, the bacterial expression
plasmid pQE-30 (Qiagen, Hilden, Germany) encodes a
synthetic pro-form of KLK protease with an N-terminally
located histidine-tag followed by an enterokinase cleavage
site. Bacterial cell pellets were solubilized in 6 mol/L guani-
dinium hydrochlorid, 100 mmol/L NaH2PO4, 8 mmol/L
2-mercaptoethanol, 10 mmol/L Tris/HCl, pH 8.0 and the
(nonglycosylated) recombinant protein was purified via its
histidine-tag by using nickel-nitrilotriacetic acid agarose af-
finity chromatography (Qiagen). KLK4 was eluted with 8
mol/L urea, 100 mmol/L NaH2PO4, 8 mmol/L 2-mercapto-
ethanol, 10 mmol/L Tris/HCl, pH 4.0, after washing by step-
wise lowering of the pH from 8.0 to 4.5. The protein was
incubated with 10 mmol/L DTT overnight at 25°C and then
dialyzed against the 100-fold volume 4 mol/L urea, 50
mmol/L of Tris/HCl, pH 8.0, 100 mmol/L NaCl, and 0.005%
Tween-20 for 12 hours. Refolding of KLK4 was performed in
2 mol/L urea, 50 mmol/L Tris/HCl, pH 8.0, 100 mmol/L NaCl,
5 mmol/L reduced glutathione, 0.5 mmol/L oxidized gluta-
thione (Sigma; GSH:GSSG ratio 10:1), 2 mmol/L CaCl2,
0.002% NaN3, 0.005% Tween-20, pH 8.0 in the 100-fold
volume of the sample at 4°C for 40 hours and subsequently
in the 100-fold sample volume of the same buffer containing
1 mol/L urea, at 4°C for 24 hours. The refolding buffer was
KLK4 Activates PAR1 in Colon Cancer 1453
AJP March 2010, Vol. 176, No. 3
twice exchanged with 100 mmol/L NaCl, 50 mmol/L Tris/
HCl, 0.002% NaN3 at pH 8.0, incubated for 24 hours each.
After refolding, soluble KLK4 was incubated with porcine
enterokinase (Genscript, Piscataway, NJ) resulting in re-
moval of the N-terminal histidine tag along with the enteroki-
nase site. Enterokinase was removed using an immobilized
antibody (Sigma) and active KLK4 was purified by benza-
midine-sepharose affinity chromatography (Amersham Bio-
sciences, Little Chalfont, UK). KLK4 activity was checked
against the synthetic substrate Boc-Val-Pro-Arg-AMC (I-
1120; Bachem, Germany Bubendorf, Switzerland) and
against the macromolecular substrate pro-urokinase
(Gru¨nenthal, Aachen, Germany) as previously described.29
Generation of Polyclonal Antibodies Directed to
KLK4
Hens were immunized intramuscularly (pectoral muscle)
with 20 g of the recombinant pro-enzyme form of KLK4
(see above) per injection following the protocol by McKi-
ernan et al.30 Antibodies were isolated from egg yolk
using a standard step precipitation procedure using in-
creasing concentrations of polyethylene glycol (PEG pre-
cipitation). This procedure yielded approximately 95%
pure IgY (avian analogue of IgG; SDS–PAGE). Monospe-
cific antibodies were further affinity purified using peptide
affinity chromatography using a peptide derived from a
flexible surface-associated loop that is specific of KLK4
(aa 109 to 122 according to the chymotrypsin numbering;
for an alignment see 31). The region selected is not
conserved among members of the KLK family. Purified
monospecific polyclonal antibodies (named pAb 617A)
were then characterized using ‘one-side ELISA’ method-
ology in which the immunogen or irrelevant proteins are
coupled to the microtiter well (Seiz et al, submitted for
publication). Specificity of the antibodies was further ver-
ified by Western blot analysis, which demonstrated reac-
tivity toward recombinant pro-KLK4, but no reactivity to-
ward related recombinant pro-enzyme forms of closely
related kallikrein-related peptidases, namely KLK2, KLK3,
as well as KLK5 to KLK15. As a control for the antibody
specificity we analyzed KLK4 expression using immunohis-
tochemistry analysis on a panel of normal and pathological
human tissue sections. We found that KLK4 expression
pattern (Seiz et al, submitted for publication) is consistent
with the pattern reported by others.24,32
Immunohistochemistry
Immunohistochemistry was performed on archival forma-
lin-fixed paraffin-embedded tissue samples from normal
colonic mucosa and colonic adenocarcinomas (Pathol-
ogy Department of Bichat-Claude Bernard Hospital,
Paris). Tissues were used in accordance with the require-
ment of the Human Research Committee of the Bichat-
Claude Bernard Hospital and according to the French
bioethical law.33 After deparaffinization by xylene and
rehydration in serial ethanol dilutions, tissue sections un-
derwent heat-induced antigen retrieval by pressure cook-
ing for 4 minutes in 0.01 mol/L citrate buffer (pH 6.0).
Subsequently, endogenous peroxidase was blocked ap-
plying 0.5% H2O2 for 10 minutes at room temperature.
Sections were then incubated overnight at 4°C with chicken
pAb 617A (1:700 dilution), before a rabbit anti-chicken IgG
(Jackson ImmunoResearch Laboratories, Inc., West Grove,
PA) was applied for 30 minutes. In identically treated control
sections, primary antibody was either omitted or replaced
by green antibody diluent (Dako, Hamburg, Germany) or
neutralized with a 20-fold excess of the immunogen. Spe-
cific binding of the antibody was detected using the EnVi-
sion peroxidase polymer system with 3,3-diaminobenzi-
dine as chromogen (Dako). Sections were counterstained
with Mayer’s hemalum and coverslipped with Assistant
Histokitt.
Immunofluorescence Staining
PAR1 and PAR2 immunofluorescence detection was
performed on HT29 cells grown on glass coverslips.
The monoclonal PAR2 antibodies mAb 13-8 is directed
against 24 aa in the extracellular N-terminal region of
PAR2. The amino acid identity between PAR2 and PAR1
in the 24-aa stretch is 17% and is even less for PAR3 and
PAR4. Thus it is highly unlikely that mAb 13-8 will recog-
nize any of the other PAR family members. The mAb 13-8
specificity has been tested by flow cytometric analysis on
CHO cells stably transfected with human PAR2 com-
pared with parental CHO cells. Moreover, mAb 13-8
blocks specifically trypsin mediated calcium mobiliza-
tion, whereas thrombin-mediated calcium mobilization is
unaffected by the PAR2 antibody (Virca et al, unpub-
lished data).
We also performed immunofluorescence studies after
incubation of HT29 cells for various times (5, 10, 15, 30,
and 60 minutes) at 37°C with either thrombin (0.01 mol/
L), trypsin (0.01 mol/L), or KLK4 (1 mol/L). Cells were
washed three times in PBS before being fixed in 2%
paraformaldehyde, washed three times in PBS, and then
incubated with PBS containing 2% BSA for 15 minutes
before application of the primary anti-PAR1 (WEDE-15) or
anti-PAR2 (mAb 13-8) antibodies for 2 hours at room
temperature at a 1:100 and 1:200 dilution, respectively.
Cells were washed in PBS containing 1% BSA and sec-
ondary antibody, goat anti-mouse IgG coupled to fluo-
rescein, was applied for 45 minutes at room temperature.
The cells were washed again in PBS containing 1% BSA,
and finally washed in PBS. Negative controls were ob-
tained by omitting primary antibodies. The cells were
then mounted in Vectashield medium (Vector, Peterbor-
ough, UK). Images were examined under a fluorescence
microscope (Leica DM IRB; magnification 630).
Intracellular Calcium Measurement
Intracellular calcium concentration was measured using
Fura-2/AM. HT29 cells were seeded onto the center of
glass coverslips and cultured in Dulbecco’s modified
Eagle’s medium to 80% confluence. Coverslips were then
loaded with 5 mol/L of Fura-2/AM in Na-Hepes-buffered
saline (saline pH 7.4, containing 135 mmol/L NaCl, 4.6
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mmol/L KCl, 1.2 mmol/L MgCl2, 11 mmol/L HEPES, 11
mmol/L glucose with or without 1.5 mmol/L CaCl2) con-
taining 0.01% pluronic acid for 45 to 60 minutes at 37°C.
They were then washed in Na-HEPES buffer and placed
at 37°C in a fluorimeter. Cells were treated with KLK4,
thrombin, or human trypsin or the PARs agonists pep-
tides TRAP (SFLLR-NH2) and AP1 (TFFLR-NH2), and
changes in intracellular Ca2 were monitored. Fluores-
cence was measured using a dual-wavelength excitation
fluorimeter at 340 and 380 nm for excitation and 510 nm
for emission.
Western Blot Analysis
For ERK phosphorylation assays, cells were grown in
six-cluster wells (Costar) to 70% confluence and serum-
deprived for 48 hours. Quiescent cells were treated with
test substances for various time periods as indicated.
Cells were lysed with RIPA buffer (1 PBS, 1% Nonidet
P-40, 0.5% sodium deoxycholate, and 0.1% sodium
dodecyl sulfate) containing protease inhibitor cocktail
(Sigma) and 1 mmol/L sodium orthovanadate for 30 min-
utes at 4°C, and lysates were centrifuged at 12,000g for
15 minutes. Equal amounts of extracts (50 g) were
separated by SDS–PAGE and transferred onto nitrocel-
lulose membrane. Membranes were incubated in block-
ing Tris-buffered saline buffer (20 mol/L Tris, 50 mol/L
NaCl) containing 5% (w/v) low-fat milk and 0.1% (v/v)
Tween 20 and then probed with phospho-specific anti-
bodies to ERK1/2 (1:2000) overnight at 4°C. Subse-
quently, blots were washed and incubated with the anti–
IgG-peroxidase–linked secondary antibody for 1 hour at
room temperature before detection by use of a chemilu-
minescent detection kit (NEN Life Science, Paris, France)
and exposure to X-ray film. Membranes were reprobed
with a polyclonal anti-ERK1/2 antibody (1:1000) that rec-
ognizes total ERK1/2 regardless of its phosphorylation
state and served as loading control.
Results
KLK4 Is Expressed in Colon Cancer Tumors
in Vivo
We analyzed KLK4 expression in human colonic adeno-
carcinomas versus normal colonic epithelium by immu-
nohistochemistry using p617A, the KLK4-specific poly-
clonal antibody (for details see Materials and Methods
section). A discrete immunoreactivity is detected in the
“normal-appearing” mucosa, from patients with colon
cancer, removed far from the neoplastic tissue (Figure
1A). Similarly, in normal colonic samples from control
patients, almost no staining was observed (not shown).
KLK4 expression is clearly seen in the mild dysplastic
mucosa contiguous to a cancerous lesion (Figure 1B),
and expression increases in intensity as the dysplasia
progresses (data not shown). Staining is localized in the
columnar absorptive cells and in goblet cells; however,
the intensity of labeling varies among the different pa-
tient’s adenocarcinomas analyzed as shown in (Figure 1,
C–E). KLK4 is observed mainly in the cytoplasm of can-
cer cells. No specific staining was seen in negative con-
trol sections where the primary antibody was omitted (not
shown) or preabsorbed with 20-fold excess of recombi-
nant KLK4 (Figure 1F). These observations show that
human colonic adenocarcinomas aberrantly express
higher levels of KLK4 than normal mucosa and suggest
that the also upregulated PARs11–13 may represent po-
tential substrates for KLK4 in this pathology.
KLK4 Induces Loss of PAR1 and PAR2 from
the Cell Surface of Colon Cancer–Derived Cell
Line HT29
Because PAR4 is expressed at very low levels in colon
cancer cell lines in general and specifically in HT29
cells,13 only PAR1 and PAR2 were analyzed in this study.
Figure 1. Representative immunostaining of the KLK4 in paraffin sections of
normal-appearing colonic mucosa and colonic tissues from patients with
adenocarcinoma. A: Faint epithelial KLK4 immunoreactivity in “normal-ap-
pearing” mucosa removed far from the cancerous lesion. Positive KLK4
staining is also seen in the lamina propria and in a few macrophages
(arrow). B: Immunostaining for KLK4 in the dysplastic colonic mucosa close
to the cancerous lesion seen in D. C–E: Moderate to strong positive immu-
noreactivity in the adenocarcinomas of three different patients. F: In the same
carcinoma as in E, no immunoreactivity is detected when the primary anti-
body is preadsorbed with 20-fold excess of recombinant KLK4. Scale bar 
100 m (A and B), 200 m (C and D), or 400 m (E and F).
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By using immunofluorescence microscopy with antibod-
ies directed against the N-terminal domains of either
PAR1 and PAR2, we examined the loss of PAR1 and
PAR2 immunoreactivity at the cell surface of KLK4-
treated cells, a finding that may reflect receptor internal-
ization.34 As shown in Figure 2, PAR1 and PAR2, which
are expressed on HT29 cells,11,12 were readily detected
at the plasma membrane of unstimulated HT29 cells.
Stimulation of HT29 cells with KLK4 (1 mol/L) for 5
minutes resulted in a decrease of PAR1 and PAR2 immu-
noreactivity at the cell surface (Figure 2). Longer stimu-
lations of the cells with thrombin or KLK4 resulted in an
increased loss of PAR1 receptor immunoreactivity from
the cell surface, with nearly complete loss at 30 to 60
minutes (not shown). In controls and as expected, throm-
bin and trypsin treatment also caused PAR1 and PAR2
internalization, respectively (Figure 2).5,34 Interestingly,
immunostaining of PAR1 was not significantly affected by
trypsin treatment (Figure 2). Similarly, thrombin treatment
did not affect PAR2 staining. These data indicate that
KLK4 mediates both PAR1 and PAR2 N-terminal cleav-
age and loss of the receptor staining from HT29 cell
surface.
Calcium Signaling Triggered by KLK4 Is
Mediated by PAR1 but Not by PAR2
The immunofluorescence analysis data suggest that the
loss of PAR1 and PAR2 seen in KLK4-treated HT29 cells
is attributable either to receptor internalization or cleav-
age upstream or downstream of the activation site, the
latter process often referred to as receptor disarming.6
PAR-mediated calcium mobilization requires proteolytic
cleavage at a specific activation site.5,6 Therefore, we
investigated whether KLK4 can trigger calcium signaling
in HT29 cells that constitutively express PAR1 and
PAR2.11,12 On cell exposure to 0.5 mol/L of KLK4, a very
small peak of intracellular Ca2 mobilization was de-
tected (data not shown), whereas, as shown in Figure 3,
HT29 cells challenge with 1 mol/L of KLK4 initiated a
significant transient Ca2 mobilization (Figure 3A). Posi-
tive control agonists for PAR1 (thrombin) and PAR2 (tryp-
sin) each induced changes in Ca2 mobilization in HT29
cells (Figure 3, B and C), confirming that the receptors
Figure 2. KLK4 induces loss of PAR1 and PAR2 from the surface of colonic
cancer HT29 cells. HT29 cells were treated with thrombin (0.01 mol/L),
trypsin (0.01 mol/L), KLK4 (1 mol/L; stimulated), or with vehicle (un-
stimulated) for 5 minutes at 37°C. Cells were fixed using 2% paraformalde-
hyde and immunostained with PAR1 or PAR2 monoclonal antibodies that
recognize epitopes within the N-terminal extracellular domains of PAR1 and
PAR2, respectively (630). Results are representative of two independent
experiments.
Figure 3. KLK4 induces calcium mobilization in HT29 cells. HT29 cells were
loaded for 60 minutes at 37°C using Fura-2/AM. Cells were challenged with
(A) KLK4 (1 mol/L), (B) thrombin (0.01 mol/L), or (C) trypsin (0.01
mol/L). Addition of the enzymes is indicated by arrows. These results are
representative of three others.
1456 Gratio et al
AJP March 2010, Vol. 176, No. 3
(PAR1 and PAR2) expressed on HT29 are functional. As
a control, no transient Ca2 mobilization was seen when
heat-inactivated KLK4 was added to HT29 cells (data not
shown).
The specificity of the response via PAR1 and for PAR2
was demonstrated by cross desensitization studies using
a specific agonist peptide.10,35 As shown in Figure 4A, a
challenge of the cells with TRAP (SFLLR-NH2; 100 mol/
L), which is known to desensitize PAR1 and PAR2 but not
other PARs,10 abrogated subsequent KLK4-induced
Ca2 flux. Similarly, thrombin and trypsin, the known
agonists of PAR1 and PAR2, respectively, had no effect
on calcium mobilization after an initial challenge with
TRAP (SFLLR-NH2; Figure 4, B and C). To check the
integrity of the cells, carbachol (50 mol/L)36 was sub-
sequently added of to the same cells and gave the ex-
pected response (Figure 4, A–C). These experiments
suggest that KLK4 signals mainly via PAR1 and/or PAR2.
To determine which PAR is activated by KLK4, we
used monoclonal antibodies directed against the se-
quence spanning the cleavage sites of PAR1 (SPAN-12)
or PAR2 (mAb 13-8) (Virca et al, unpublished results, and
this study). As shown in Figure 5A, the SPAN-12 antibody
efficiently blocked PAR1 cleavage by thrombin, as very
little, if any, Ca2 influx was detected. Interestingly,
KLK4–induced Ca2 mobilization was also abrogated,
whereas trypsin-mediated responses were not signifi-
cantly affected (Figure 5A). On the other hand, blocking
cleavage of PAR2 with the monoclonal antibody antago-
nist mAb 13-8 completely abrogated trypsin-induced
Ca2 influx, and was without significant effect on the
KLK4-induced Ca2 flux (Figure 5B). Consistent with
these findings, in the presence of PAR2 blocking anti-
body, KLK4 induced Ca2 mobilization, and subsequent
incubation with thrombin led to a dramatically reduced
signal indicating that KLK4 desensitized most of PAR1 in
HT29 cells (Figure 5C). The KLK4-induced loss of PAR2
immunostaining at HT29 cell surface seen in Figure 2
may be attributable to PAR2 cleavage at a site upstream
of the activation site without any further consequences on
the functionality of the receptor. In concordance with
these data, after complete desensitization of PAR1 by the
PAR1-specific peptide AP1 (TFFLR-NH2; 100 mol/L)
subsequent incubation with KLK4 did not induce any
Ca2 elevation (Figure 5D). As expected, desensitization
of PAR2 by the PAR2-specific peptide 2-furoyl-LIGRLO-
NH2 did not affect subsequent KLK4-induce Ca
2 eleva-
tion (data not shown). As control, addition of carbachol to
the same cells in Figure 5 (C and D) induced Ca2
elevation, showing the absence of intracellular calcium
depletion in the cells (data not shown). These results
strongly suggest that KLK4 activates preferentially PAR1
and not PAR2 in HT29 cells.
KLK4 Enhanced ERK1/2 Activation in Human
Colon Cancer Cells
Because we have previously shown that PAR1 and PAR2
activation plays a pivotal role in extracellular-regulated
kinase (ERK1/2)-induced activity in colon cancer,12,14,15
we next investigated the effect of KLK4 on ERK1/2 phos-
phorylation. Addition of KLK4 (1 mol/L) to quiescent
HT29 cells for various times induced a rapid and signif-
icant phosphorylation of p42/p44, reaching a maximum
within 5 to 10 minutes (Figure 6A). KLK4 induces ERK1/2
phosphorylation in the range of concentrations between
0.01 mol/L and 0.5 mol/L. Significant ERK1/2 phos-
phorylation was obtained already with 0.01 mol/L of
KLK4, which is comparable with the signal seen with 0.01
mol/L of thrombin at 5 minutes (Figure 6B). These ex-
periments suggest that KLK4 signals via PAR1 to activate
the MAP kinase pathway in colon cancer cells and pos-
sibly playing an important role in colon tumorigenesis.
Figure 4. KLK4 signals via PARs in HT29 cells. HT29 cells were loaded for 60
minutes at 37°C using Fura-2/AM. A: Cells were challenged by addition of
TRAP (SFLLR-NH2; 100 mol/L) followed by a second challenge with KLK4
(1 mol/L). B: The cells were challenged first with the activating peptide
TRAP (SFLLR-NH2; 100 mol/L) followed by a second challenge with throm-
bin (0.01 mol/L). C: The cells were challenged first with the activating
peptide TRAP (SFLLR-NH2; 100 mol/L) followed by a second challenge with
trypsin (0.01 mol/L). Note that cells are still responsive to a third challenge
with carbachol (50 mol/L; A–C). All of the compounds were given at the
arrows. These results are representative of two others.
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Discussion
We report here that KLK4, a member of the tumor-asso-
ciated KLK family, is ectopically expressed in human
colon cancer cells. To our knowledge, this is the first
evidence of KLK4 expression in colon cancer. In con-
trast, KLK4 is barely detected in epithelial cells of normal
human colon. In the colon cancer–derived cell line HT29,
KLK4 appears to promote efficient calcium mobilization
through the ectopically expressed receptor PAR1 and
subsequent ERK1/2-MAP kinase activation. Therefore,
KLK4 could be considered as a potential endogenous
PAR activator in colon cancer owing to the aberrant ex-
pression of its receptor PAR1.
Our observation of the increased expression of KLK4
in colon cancer tumors relative to normal colonic epithelia
parallels with our previous results showing aberrant ex-
pression of PAR1 in colonic adenocarcinomas compared
with the normal mucosa.12 In fact, KLK4 is coexpressed
in tumors that have been shown to express PAR1 (data
not shown). The low level of KLK4 in normal colonic
tissues is in agreement with two previous reports. First,
Shaw and coauthors reported an absence of KLK4 in
normal colonic tissue extracts by ELISA.32 Second, Kon-
tos et al reported recently that KLK4 mRNA is upregu-
lated in colon cancer compared with normal colon.37
However, an in silico analysis of kallikrein-related pepti-
dase gene expression in colon cancer did not report the
presence of detectable KLK4; this discrepancy with our
findings may be attributable to differences in sensitivity
between the two detection methods.38 The mechanism
whereby the KLK4 gene is switched on in colon cancer is
unknown, but this ectopic expression could possibly be
under the same gene regulation as in other cancers.
Indeed, KLK4 has been reported to be highly expressed
in breast carcinoma,25 prostate adenocarcinoma,39 and
ovarian adenocarcinoma.40 Specific CpG dinucleotides
in the proximal promoter have been shown to regulate
gene expression of some human KLKs, including KLK4
via DNA methylation.41
Additional studies are required to determine whether
endogenously released KLK4 contributes to colon can-
cer development. KLK4 is synthesized and secreted as a
zymogen.23,42 This fact raises the question of how endo-
Figure 5. KLK4 initiates changes in intracellular
Ca2 mobilization via PAR1 but not PAR2 in HT29
cells. HT29 cells were preincubated for 2 hours
with or without antibodies directed against PAR1
(A) or PAR2 (B and C) activation site and then
were loaded with Fura-2/AM for 60 minutes. A:
Cells preincubated with anti-PAR1 were first chal-
lenged with thrombin (0.01 mol/L) followed by a
second challenge with KLK4 (1 mol/L) and a
third challenge with trypsin (0.01 mol/L). B: Cells
preincubated with anti-PAR2 were challenged first
with trypsin (0.01 mol/L) followed by a second
challenge with KLK4 (1 mol/L). Note that cells
are still responsive to KLK4 in the presence of
PAR2 blocking antibodies. C: Cells preincubated
with anti-PAR2 were challenged with KLK4 (1
mol/L) and then with thrombin (0.01mol/L).D:
HT29 cells were challenged first three times with
the activating peptide AP1 (TFFLR-NH2; 100
mol/L) and then with KLK4 (1 mol/L). Note that
AP1 (TFFLR-NH2) abrogated KLK4 response. All of
the compounds were given at the arrows. These
results are representative of three others.
Figure 6. KLK4 activates p42/p44 MAPK in HT29 cells. A: Immunoblot with
phospho-specific p42/p44 MAPK antibodies on quiescent HT29 cell lysates
treated with or without KLK4 (0.5 mol/L) or thrombin (0.01 mol/L) for the
indicated time periods (shown in minutes). B: Dose-dependent activation of
p42/p44 MAP-kinase phosphorylation by KLK4. Quiescent HT29 cells were
stimulated with the indicated concentrations of KLK4 or with thrombin (0.01
mol/L) for 10 minutes. To confirm equal protein loading, the membranes
were stripped and incubated with p42/p44 antibodies. Results are represen-
tative of two independent experiments.
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genously released KLK4 might contribute to colon tumor-
igenesis. Although physiological activators of KLK4 have
not been reported, in vitro biochemical studies suggest
that some KLKs may participate in an enzymatic cascade
to activate each other.43 Whether these KLKs also pro-
cess pro-KLK4 has yet to be demonstrated.
Our data from microscopic analysis clearly showed a
loss of both PAR1 and PAR2 from the cell surface of HT29
cells after KLK4 incubation. Further analysis of calcium
mobilization in HT29 cells that express both PAR1 and
PAR211,12 have yielded important insights into the ability
of KLK4 to induce signaling via PAR1 but not PAR2. In
enzymatics experiments we performed to test the capac-
ity of this enzyme to cleave peptidic substrates mimicking
PAR1 and PAR2, we found that KLK4 cleaves both re-
ceptor-derived PAR1 and PAR2 peptides in vitro (data not
shown). This is consistent with previously reported obser-
vations that cleavage of peptides spanning the activation
site of PARs by trypsin or thrombin may not accurately
reflect the ability of enzymes to activate and/or disarm
their respective receptors on intact cells44 and further
that individual KLKs can function as both an activator and
a disarmer of individual PARs.19
Several lines of evidence indicate that KLK4 signals in
HT29 cells only through PAR1 but not PAR2: (i) PAR1 block-
ing antibodies abrogated completely the effect of KLK4 on
calcium transients; (ii) desensitization of PAR1 with AP1
(TFFLR-NH2), which specifically targets PAR1,
45 abrogated
all KLK4–induced calcium transients; (iii) blocking cleavage
of PAR2 with a monoclonal antibody antagonist failed to
attenuate the KLK4-induced Ca2 flux. The observation that
PAR1 blocking antibodies abrogated completely the effect
of KLK4 on calcium transients whereas the response to
trypsin remained intact suggests that KLK4 cleavage of
PAR2, in a cellular context, is probably upstream of the
activation site.
Our results are consistent with two recent reports
showing that KLK4 can signal in prostate cancer cell lines
by a PAR-dependent mechanism.21,22 In contrast, in
these studies, the authors reported the involvement of
both PAR1 and PAR2 in prostate cancer KLK4-induced
signaling. These discrepancies could be attributable to
differences in protease preparations, levels of receptor
expression, or cell type. Indeed, both studies were con-
ducted mostly on murine lung fibroblasts (LMF or KOLF)
from PAR1-null mice46,47 that overexpress human PAR1
or PAR221,22 or on cells overexpressing PAR2-GFP.21
Further studies on other cancer cells that naturally ex-
press PARs are necessary to clarify these issues. Another
possible explanation could be that posttranslational modifi-
cations, such as receptor glycosylation, might also affect
KLK4 signaling via PAR2. Such phenomena have been
reported for other serine proteases such as tryptase-medi-
ated activation of PAR2.48 Differential glycosylation could
potentially modify enzyme kinetic parameters or restrict
KLK4 from gaining access to the cleavage site of the
receptor.
The specificity of KLK4 toward PAR1 could be facili-
tated by direct interaction with the receptor, which might
localize the protease and allosterically modulate its ac-
tivity toward PAR1. Interestingly, KLK4 shows a nega-
tively charged surface patch, which may represent an
exosite for prime-side substrate recognition.26 Such an
interaction between the anion-binding exosite of thrombin
and an acidic region at the C terminus of PAR1 has been
shown to increase thrombin affinity toward the receptor.49
Further research is needed to establish how KLK4 acts
specifically on PAR1 to generate a functional ligand and
induce signaling. KLK4-induced PAR1 activation resulted
in rapid ERK1/2 phosphorylation in HT29 cells. Similarly,
we previously showed that PAR1 activation leads to ac-
tivation of the MAP kinase pathway in colon cancer
cells.12,15 Interestingly, we observed that KLK4-induced
ERK1/2 phosphorylation was initiated with a lower KLK4
concentration than that needed for induction of calcium
mobilization. It is possible that at this concentration, KLK4
activates the MAP-kinase pathway without calcium sig-
naling. Indeed, a recent report by Ramachandran et al50
has shown that PARs can signal through multiple path-
ways that are differentially triggered by distinct protease-
revealed tethered ligands depending on the site cleav-
age. It is of note that at low concentrations KLK4 could
process membrane proteins other than PARs, such as
the urokinase-receptor,29 and, thus, potentially, signal via
alternative pathways. On the other hand, PAR-dependent
ERK1/2 activation by KLK4 might also be initiated via a
calcium independent pathway leading to activation of re-
ceptor tyrosine kinases signaling.15 The mechanism by
which KLK4 induces PAR1 signaling in colon cancer is not
known, but it is possible that activation of PAR1 by KLK4
couples with different effectors and elicits distinct cellular
responses than that induced by thrombin. Such mechanism
has been recently reported for activated protein C by Russo
et al who revealed that compartmentalization of PAR1 in
caveolae is critical for protease-selective signaling.51,52
Whether KLK4 signaling through the aberrantly ex-
pressed PAR1 in colon cancer can directly influence
tumor development in vivo clearly deserves further inves-
tigations. However, concomitant upregulation of KLK4
and PAR1 in colonic tumors would suggest that KLK4-
mediated PAR1 activation could play an important role in
colon tumorigenesis.
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